Publication details
Komentář k doporučeným postupům ESC/ČKS Farmakoterapie srdečního selhání
| Title in English | Comment on ESC/CSC Guidelines Heartfailure pharmacotherapy |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Kardiologická revue - Interní medicína |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | heart failure; pharmacotherapy; ACE inhibitors; sacubitril/valsartan |
| Description | The main goal of heartfailure treatment is to reduce mortality and morbidity, improve the quality of life and reduce the numberof hospitalisations. ACEinhi-bitors are the corner-stone of the treatment, complemented with MRA. AHA are indicated in the čase of ACE-I intolerance. The results of the PARADIGM-HF trial indicate that ACE-I can be replaced with sacubitril/valsartan in symptomatic patients. ACE-I oř AHA are recommended in maximal tolerated doses. Beta bloc-kers should be added to the renin angiotensin blockade in maximal tolerated doses. Diuretics are given to relieve symptoms such as dyspnoea oř oedema. Adding digoxin is indicated in selected patients. The use of statíns, anticoagulation oř antiaggregation drugs is recommended according to their basic indica-tion (IHD, atrial fibrillation). Heart failure is not a spedfic indication for their use, but neither is it a contraindication. |